# A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer

Source: https://onco.cc/trials/nct07647328/  
OnCo record `nct07647328` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Camizestrant and Ribociclib in HR-positive / HER2-negative breast cancer, run by AstraZeneca, now recruiting.

## Summary

A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer is a phase 3 interventional study registered as NCT07647328 by AstraZeneca, with 150 participants planned, started 2026-06-15 and due to reach its primary completion in 2029-02-28. Interventions recorded: Camizestrant and Ribociclib.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07647328
- Phase: 3
- Setting: SERAFA-1: A Single Arm, Open Label, Multicentre, Phase IIIb Study Of Camizestrant Plus Ribociclib in 1st Line Treatment of ER Positive, HER2-negative Advanced Breast Cancer Patients
- Sponsor: AstraZeneca
- Enrolled: 150

## Sources

- ClinicalTrials.gov NCT07647328: https://clinicaltrials.gov/study/NCT07647328

## Connected records

- cancers: [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/)
- drugs: [Camizestrant](https://onco.cc/drugs/camizestrant/), [Ribociclib](https://onco.cc/drugs/ribociclib/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/), [ICON plc](https://onco.cc/companies/icon-plc/)

---
JSON: https://onco.cc/api/v1/entities/nct07647328.json